Platelet-Derived Soluble CD40L and Its Impact on Immune Modulation and Anti-IL6R Antibody Treatment Outcome in Rheumatoid Arthritis
This study highlights the diminished ability of RA PLTs to suppress T lymphocyte activation and that sCD40L can be a potential biomarker and therapeutic target in RA.
Authors
- Patricia Moya (ORCID: https://orcid.org/0000-0001-8339-5420)
- Diego Collado
- Hye Sang Park (ORCID: https://orcid.org/0000-0002-4972-9527)
- Rubén Osuna‐Gómez (ORCID: https://orcid.org/0000-0003-2875-4405)
- Maria Mulet (ORCID: https://orcid.org/0000-0003-3639-3291)
- Maisa García-Arguinzonis
- Hèctor Corominas (ORCID: https://orcid.org/0000-0002-7738-6787)
- Cèsar Díaz‐Torné (ORCID: https://orcid.org/0000-0001-6275-7699)
- Carla Pitarch (ORCID: https://orcid.org/0000-0002-6015-244X)
- Elisabet Cantó (ORCID: https://orcid.org/0000-0002-1782-1855)
- Sílvia Vidal (ORCID: https://orcid.org/0000-0002-3909-6682)
- Carlos Zamora (ORCID: https://orcid.org/0000-0001-8532-9646)
- Ma Àngels Ortiz (ORCID: https://orcid.org/0000-0002-1574-9861)
Institutions
- Universitat Autònoma de Barcelona (ES)
- Hospital de Sant Pau (ES)
- Hospital Quirón Teknon (ES)
Publication Details
- Journal
- Cells
- Published
- 2025-04-22
- DOI
- https://doi.org/10.3390/cells14090625
- Citations
- 3
- Primary Topic
- Platelet Disorders and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 5.31
Funders
- Instituto de Salud Carlos III